Vaginal Atrophy: The Wake-Up Call
This is an internet-based activity that should take 1 hour to complete.
To participate in this webinar learners should:
- Take the pretest
- Listen to webinar
- Take the post-test
- Complete follow-up evaluation survey
At the conclusion of this presentation, participants should be able to:
- Recognize symptoms common to vaginal atrophy and associated co-morbidities of decreased estrogen levels
- Identify women at risk for or already suffering from debilitating vaginal atrophy
- Conduct appropriate screening, counseling, risk assessment, and treatment activities using an interdisciplinary approach
- Implement customized prevention and treatment strategies, including hormone therapy when appropriate
Physicians: The Association of Reproductive Health Professionals is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ARHP designates this internet enduring material for a maximum of 1.0AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses: This activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for up to 1.0 contact hours, including up to 0.75 pharmacology hours. Credit can be applied toward the nursing continuing education requirements of most professional organizations and State Boards of Nursing.
Pharmacists: The Association of Reproductive Health Professionals (ARHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hour of continuing education credit.
Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 CreditTM.
This program is sponsored by the Association of Reproductive Health Professionals.
This project is funded through educational grants from NovoNordisk and Endo Pharmaceuticals.
All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.
Advisory Committee Disclosures
Gloria A. Bachmann, MD (Planner)
Department of Obstetrics, Gynecology and Reproductive Sciences
Associate Dean of Women’s Health
Director of the Women’s Health Institute
Professor of Obstetrics & Gynecology
Professor of Medicine
University of Medicine & Dentistry of New Jersey
Robert Wood Johnson Medical School (RWJMS)
Chief of Ob/Gyn Service and Women’s Services
Director, Executive Health Program
Robert Wood Johnson University Hospital (RWJUH)
Dr. Bachmann receives consulting fees from NovoNordisk, Shinogi, Quintiles, Endoceutics and has contracted research from Shinogi, Endoeutics.
Barbara Malat, CNP, PA-C (Planner)
Olmstead Medical Center
Migrant Health – Family Practice with focus on Women’s Health
Ms. Malat has no affiliations to disclose.
Cheryl Iglesia, MD (Planner)
Departments of Ob/Gyn and Urology
Georgetown University School of Medicine
Director, Section of Female Pelvic Medicine and Reconstructive Surgery (FPMRS)Dr. Iglesia has no affiliations to disclose.
MedStar Washington Hospital Center
ARHP Staff/Consultant Disclosures
Ellen Cohen, Cert Ed, Dip Ed
Director of Education
Nothing to disclose
Delysha D’Mellow Henry, MPH
Program ManagerNothing to disclose
Beth Jordan, MD
Nothing to disclose
Consultant (Medical Writer)Nothing to disclose